Yang Liao

Yang Liao

Associate

Yang Liao is an associate in the Shanghai office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on mergers and acquisitions and capital market transactions.

Before joining the firm, Yang practiced as an associate for Fandga Partners and served as legal counsel for Lilly Asia Ventures. She has represented clients in various industries including life sciences, semiconductors, technology, media, and telecom (TMT), and logistics with a business focus in the China market.

Experience

Yang Liao is an associate in the Shanghai office of Wilson Sonsini Goodrich & Rosati, where her practice focuses on mergers and acquisitions and capital market transactions.

Education

LL.M., New York University School of Law, 2017
LL.B., China University of Political Science and Law, 2016

Admissions

State Bar of New York
Qualified in People's Republic of China

Credentials

Education

LL.M., New York University School of Law, 2017
LL.B., China University of Political Science and Law, 2016

Admissions

State Bar of New York
Qualified in People's Republic of China

Recent Insights

Client Highlights

On June 6, 2024, Plutonian Acquisition Corp. (Plutonian) completed its initial business combination with Big Tree Cloud International Group Limited (Big Tree Cloud). On June 7, 2024, the latter began trading its shares and warrants on the Nasdaq Stock Market under the symbols “DSY” and “DSYW,” respectively.

Plutonian is a Delaware corporation incorporated as a blank check company, or special purpose acquisition company (SPAC), for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. Big Tree Cloud is a company devoted to the development, production, and sales of personal care products and other consumer goods in China.

Learn More

Client Highlights

On April 8, 2024, D3 Bio, Inc., a globally orientated, clinical-stage biotechnology company that focuses on the discovery, development, and registration of new medicines in oncology and immunology, announced its closing of a $62 million Series A+ financing. The financing was led by Medicxi, a leading European life sciences investment firm, with participation by existing investors Matrix Partners China and WuXi AppTec’s corporate venture fund. The funding will be allocated to expedite the development of D3 Bio’s assets through preclinical and clinical stages, with a particular focus on accelerating the global clinical trial of D3S-001, a new generation small molecule KRAS G12C inhibitor with the best-in-class potential. D3S-001 is currently in Phase II development in non-small cell lung cancer, colorectal cancer, and pancreatic cancer.

Wilson Sonsini advised existing investors, including Matrix Partners China and WuXi AppTec’s corporate venture fund, on this transaction. The Wilson Sonsini team was led by partner Jie Zhu, and included Jill Sheng, Xuchao Dong, and Yang Liao.

Learn More